AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 5 out of 5

Recs

1
Player Avatar DirkaDirka (83.23) Submitted: 3/15/2013 6:18:57 PM : Outperform Start Price: $35.39 ABBV Score: +10.48

Some P/E ratios for comparison:
BMY 33.79
MRK 21.99
PFE 22.24
JNJ 20.50

And...
ABBV 12.44

P/E isn't everything, but ROE and ROA are pretty outstanding as well in comparison. Yes there are worries about being reliant on one drug, but there's plenty of time to bail if nothing promising comes down the pipeline. In the meantime, revenues from Humira are increasing, which means good things for about 2 more years at least. This is a classic undervalued spinoff, despite the large size.

Featured Broker Partners


Advertisement